A Pilot Meta-research on Evolving Evidence Behind Genetic Variant (Re)Classification.

Area of Science:

• Genomic medicine
• Clinical genetics
• Bioinformatics

Background:

• Variant classification is crucial for precision medicine.
• Variants of Uncertain Significance (VUS) in BRCA1 and BRCA2 require careful reclassification.
• Current reclassification practices may have limitations.

Purpose of the Study:

• To evaluate the accuracy, completeness, and currency of evidence supporting VUS reclassifications in BRCA1 and BRCA2.
• To identify patterns and potential deficiencies in the literature and data used for VUS reclassifications.
• To inform improvements in genomic variant reclassification for better clinical decision-making.

Main Methods:

• Systematic analysis of 162 unique cited publications supporting VUS reclassifications.
• Examination of citation accuracy, completeness, and temporal alignment with ClinVar submissions.
• Identification of common themes in cited studies, including classification recommendations, genetic mechanisms, computational tools, and population diversity.

Main Results:

• Inadequate or missing evidence was found supporting numerous VUS reclassifications.
• Temporal misalignment between citations and ClinVar submissions was observed.
• Cited studies frequently employed classification recommendations, genetic mechanisms, computational tools, and population data, but diversity was limited.

Conclusions:

• There is a critical need for more robust evidence to support VUS reclassifications in BRCA1 and BRCA2.
• Improving the accuracy and timeliness of citations and ClinVar submissions is essential.
• Enhanced inclusion of diverse populations in studies is necessary to optimize genomic variant reclassification and clinical utility.